\-\ Texto\\:\\ \ \(0\)\
\-\ not\\ available\\.\ \(14\)\
\-\ unknown\\.\ \(36\)\
\-\ there\\ are\\ multiple\\ area\\ of\\ hypoattenuation\\ and\\ filling\\ defect\\ within\\ the\\ right\\ and\\ left\\ pulmonary\\ arteries\\.\\ \\ there\\ is\\ a\\ comet\\ shaped\\ area\\ of\\ hypoattenuation\\ extending\\ from\\ the\\ left\\ pulmonary\\ artery\\ nearly\\ to\\ the\\ branch\\ point\\ of\\ the\\ main\\ pulmonry\\ artery\\.\ \(0\)\
\-\ pulomary\\ embolism\ \(0\)\
\-\ pulmonary\\ embolism\ \(77\)\
\-\ venous\\ thromboembolism\ \(8\)\
\-\ primary\\ thrombus\ \(1\)\
\-\ septic\\ emboli\ \(22\)\
\-\ tumor\\ emboli\ \(4\)\
\-\ 61\\ years\\-old\\ man\\ with\\ known\\ stage\\ ii\\ pancreatic\\ cancer\\.\\ \\ underwent\\ contrast\\ ct\\ of\\ the\\ chest\\,\\ abdomen\\ and\\ pelvis\\ for\\ pre\\-operative\\ evaluation\\.\ \(0\)\
\-\ venous\\ thromboembolic\\ disease\\,\\ especially\\ resulting\\ in\\ pulmonary\\ embolism\\ represents\\ a\\ significant\\ disease\\ burden\\ in\\ terms\\ of\\ morbidity\\ and\\ mortality\\ in\\ hospitalized\\ and\\ non\\-hospitalized\\ patients1\\.\\ \\ thrombus\\,\\ or\\ clot\\,\\ often\\ forms\\ in\\ the\\ proximal\\,\\ deep\\ leg\\ veins\\ and\\ only\\ may\\ only\\ become\\ clinically\\ evident\\ once\\ a\\ thrombus\\ segment\\ has\\ embolized\\[1\\,\\ 2\\]\\.\\ \\ upon\\ embolization\\ from\\ a\\ vein\\ \\(in\\ the\\ proximal\\ leg\\ or\\ elsewhere\\)\\ the\\ first\\ bed\\ of\\ vessels\\ of\\ decreasing\\ diameter\\ is\\ usually\\ the\\ lungs\\,\\ where\\ the\\ embolus\\ may\\ lodge\\ occluding\\ blood\\ flow\\ and\\ creating\\ clinically\\ significant\\ or\\ insignificant\\ \\(based\\ on\\ size\\)\\ ventilation\\-perfusion\\ mismatches\\[1\\,\\ 3\\]\\.\\ \\ the\\ progression\\ from\\ thrombus\\ formation\\ in\\ the\\ legs\\ to\\ pulmonary\\ embolism\\ is\\ believed\\ to\\ account\\ for\\ up\\ to\\ 10\\%\\ of\\ hospital\\ deaths\\[1\\]\\.\\ \\ tragically\\,\\ acute\\ pulmonary\\ embolism\\ is\\ among\\ the\\ leading\\ causes\\ of\\ preventable\\ hospital\\ deaths\\ in\\ the\\ united\\ states\\[4\\]\\.\ \(0\)\
\-\ \\	detection\\ and\\ therapy\\ for\\ acute\\ pulmonary\\ embolism\\,\\ once\\ it\\ has\\ become\\ clinically\\ apparent\\ is\\ difficult\\ and\\ often\\ without\\ optimum\\ result\\.\\ \\ the\\ best\\ method\\ of\\ preventing\\ pulmonary\\ embolism\\ is\\ to\\ prevent\\ primary\\ thrombus\\ formation\\[1\\,\\ 4\\]\\.\\ \\ extensive\\ clinical\\ trials\\ have\\ resulted\\ in\\ revised\\ clinical\\ guidelines\\ in\\ 2007\\ for\\ the\\ prevention\\ and\\ management\\ of\\ venous\\ thrombosis\\ and\\ venous\\ thromboembolic\\ disease\\[2\\,\\ 5\\]\\.\\ \\ these\\ new\\ recommendations\\ state\\ that\\ \\(1\\)\\ low\\ molecular\\ weight\\ heparins\\ are\\ preferable\\ to\\ unfractionated\\ heparins\\ in\\ inpatient\\ populations\\;\\ \\(2\\)\\ low\\ molecular\\ weight\\ heparins\\ are\\ safe\\ and\\ cost\\ effective\\ for\\ treating\\ deep\\ venous\\ thrombosis\\ and\\ pulmonary\\ embolism\\ in\\ selected\\ outpatients\\;\\ \\(3\\)\\ compression\\ stocking\\ should\\ be\\ utilized\\ to\\ prevent\\ postthrombotic\\ syndrome\\ within\\ one\\ month\\ of\\ diagnosis\\ and\\ used\\ for\\ a\\ minimum\\ of\\ one\\ year\\;\\ \\(4\\)\\ there\\ is\\ inadequate\\ evidence\\ to\\ recommend\\ specific\\ types\\ of\\ anticoagulation\\ in\\ pregnant\\ women\\;\\ \\(5\\)\\ recommendations\\ on\\ length\\ of\\ treatment\\;\\ and\\ \\(6\\)\\ low\\ molecular\\ weight\\ heparin\\ is\\ safe\\ and\\ efficacious\\ for\\ long\\ term\\ treatment\\ on\\ venous\\ thromboembolism\\ in\\ selected\\ patients\\,\\ such\\ as\\ those\\ with\\ cancer\\[2\\,\\ 5\\]\\.\\ \\ for\\ additional\\ information\\ on\\ this\\ complex\\ and\\ everchanging\\ topic\\,\\ the\\ reader\\ is\\ directed\\ to\\ the\\ references\\ below\\ and\\ the\\ references\\â\\€\\™\\ references\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ embolism\\:\\ 0\\.32629382494967446\ \(0\)\
\-\ pulmonary\\:\\ 0\\.2468183491359121\ \(0\)\
\-\ heparins\\:\\ 0\\.21585256743107842\ \(0\)\
\-\ thrombus\\:\\ 0\\.20919956401789117\ \(0\)\
\-\ venous\\:\\ 0\\.19273072278887932\ \(0\)\
\-\ the\\:\\ 0\\.1705704320524339\ \(0\)\
\-\ molecular\\:\\ 0\\.1698093997496303\ \(0\)\
\-\ and\\:\\ 0\\.16734415971756458\ \(0\)\
\-\ in\\:\\ 0\\.1455008230734597\ \(0\)\
\-\ of\\:\\ 0\\.13206892351362134\ \(0\)\
\-\ deaths\\:\\ 0\\.12414020466332129\ \(0\)\
\-\ thromboembolism\\:\\ 0\\.11851389341096985\ \(0\)\
\-\ hypoattenuation\\:\\ 0\\.11701043838501539\ \(0\)\
\-\ clinically\\:\\ 0\\.11216721113504818\ \(0\)\
\-\ thromboembolic\\:\\ 0\\.11211794960007876\ \(0\)\
\-\ safe\\:\\ 0\\.11109989713001568\ \(0\)\
\-\ is\\:\\ 0\\.11089051616569759\ \(0\)\
\-\ for\\:\\ 0\\.10909210015717498\ \(0\)\
\-\ references\\:\\ 0\\.10760800907896223\ \(0\)\
\-\ hospitalized\\:\\ 0\\.10757995524740209\ \(0\)\
\-\ recommendations\\:\\ 0\\.10470395331912459\ \(0\)\
\-\ to\\:\\ 0\\.10122959088755158\ \(0\)\
\-\ selected\\:\\ 0\\.09664601708383432\ \(0\)\
\-\ weight\\:\\ 0\\.0941239716320856\ \(0\)\
\-\ emboli\\:\\ 0\\.088275707505039\ \(0\)\
\-\ once\\:\\ 0\\.08457126833365904\ \(0\)\
\-\ prevent\\:\\ 0\\.08251082137878808\ \(0\)\
\-\ become\\:\\ 0\\.07985090965663894\ \(0\)\
\-\ low\\:\\ 0\\.07744872499411323\ \(0\)\
\-\ thrombosis\\:\\ 0\\.07336456824382305\ \(0\)\
\-\ pulmonry\\:\\ 0\\.07195085581035948\ \(0\)\
\-\ patients1\\:\\ 0\\.07195085581035948\ \(0\)\
\-\ tragically\\:\\ 0\\.07195085581035948\ \(0\)\
\-\ stocking\\:\\ 0\\.07195085581035948\ \(0\)\
\-\ efficacious\\:\\ 0\\.07195085581035948\ \(0\)\
\-\ everchanging\\:\\ 0\\.07195085581035948\ \(0\)\
\-\ formation\\:\\ 0\\.07133726840488334\ \(0\)\
\-\ deep\\:\\ 0\\.0700441893702069\ \(0\)\
\-\ lodge\\:\\ 0\\.06875288390491394\ \(0\)\
\-\ mismatches\\:\\ 0\\.06875288390491394\ \(0\)\
\-\ optimum\\:\\ 0\\.06875288390491394\ \(0\)\
\-\ outpatients\\:\\ 0\\.06875288390491394\ \(0\)\
\-\ postthrombotic\\:\\ 0\\.06875288390491394\ \(0\)\
\-\ leg\\:\\ 0\\.06792869397281158\ \(0\)\
\-\ preventable\\:\\ 0\\.0664838867285756\ \(0\)\
\-\ reader\\:\\ 0\\.0664838867285756\ \(0\)\
\-\ hospital\\:\\ 0\\.06646593193738501\ \(0\)\
\-\ pulomary\\:\\ 0\\.06472391578726881\ \(0\)\
\-\ unfractionated\\:\\ 0\\.06472391578726881\ \(0\)\
\-\ occluding\\:\\ 0\\.06328591482313006\ \(0\)\
\-\ preferable\\:\\ 0\\.06328591482313006\ \(0\)\
\-\ minimum\\:\\ 0\\.062070102331660645\ \(0\)\
\-\ insignificant\\:\\ 0\\.06101691764679172\ \(0\)\
\-\ revised\\:\\ 0\\.06101691764679172\ \(0\)\
\-\ cancer\\:\\ 0\\.05993475108437721\ \(0\)\
\-\ often\\:\\ 0\\.0587136183749744\ \(0\)\
\-\ comet\\:\\ 0\\.058505219192507694\ \(0\)\
\-\ area\\:\\ 0\\.05829200739740735\ \(0\)\
\-\ populations\\:\\ 0\\.057187635364060956\ \(0\)\
\-\ cost\\:\\ 0\\.057187635364060956\ \(0\)\
\-\ clinical\\:\\ 0\\.057026720031662266\ \(0\)\
\-\ disease\\:\\ 0\\.05665722656148183\ \(0\)\
\-\ proximal\\:\\ 0\\.05621600249973255\ \(0\)\
\-\ only\\:\\ 0\\.05621600249973255\ \(0\)\
\-\ trials\\:\\ 0\\.05605897480003938\ \(0\)\
\-\ artery\\:\\ 0\\.055885165354940876\ \(0\)\
\-\ burden\\:\\ 0\\.05554994856500784\ \(0\)\
\-\ primary\\:\\ 0\\.05532957052209393\ \(0\)\
\-\ prevention\\:\\ 0\\.055071791916087263\ \(0\)\
\-\ guidelines\\:\\ 0\\.05462097383590064\ \(0\)\
\-\ on\\:\\ 0\\.054352558661084655\ \(0\)\
\-\ elsewhere\\:\\ 0\\.053789977623701045\ \(0\)\
\-\ there\\:\\ 0\\.053705675377841794\ \(0\)\
\-\ from\\:\\ 0\\.053605890274555854\ \(0\)\
\-\ creating\\:\\ 0\\.05340516134443122\ \(0\)\
\-\ preventing\\:\\ 0\\.05340516134443122\ \(0\)\
\-\ inadequate\\:\\ 0\\.052351976659562295\ \(0\)\
\-\ recommend\\:\\ 0\\.052351976659562295\ \(0\)\
\-\ embolized\\:\\ 0\\.05203000668239424\ \(0\)\
\-\ significant\\:\\ 0\\.05195395113172212\ \(0\)\
\-\ one\\:\\ 0\\.05151924279739162\ \(0\)\
\-\ are\\:\\ 0\\.051216436881127064\ \(0\)\
\-\ terms\\:\\ 0\\.051136164168092885\ \(0\)\
\-\ decreasing\\:\\ 0\\.0505920057182555\ \(0\)\
\-\ utilized\\:\\ 0\\.05033338683817054\ \(0\)\
\-\ method\\:\\ 0\\.04960482283430338\ \(0\)\
\-\ treating\\:\\ 0\\.04937619322678609\ \(0\)\
\-\ united\\:\\ 0\\.049154004754116756\ \(0\)\
\-\ heparin\\:\\ 0\\.049154004754116756\ \(0\)\
\-\ acute\\:\\ 0\\.04867712775296453\ \(0\)\
\-\ morbidity\\:\\ 0\\.04832300854191716\ \(0\)\
\-\ inpatient\\:\\ 0\\.04832300854191716\ \(0\)\
\-\ embolus\\:\\ 0\\.04812825372884705\ \(0\)\
\-\ believed\\:\\ 0\\.04812825372884705\ \(0\)\
\-\ among\\:\\ 0\\.047571281028939934\ \(0\)\
\-\ directed\\:\\ 0\\.04739403381280995\ \(0\)\
\-\ pregnant\\:\\ 0\\.04722068245706198\ \(0\)\
\-\ or\\:\\ 0\\.04695499845109108\ \(0\)\
\-\ clot\\:\\ 0\\.046885007577778415\ \(0\)\
\-\ forms\\:\\ 0\\.046885007577778415\ \(0\)\
\-\ detection\\:\\ 0\\.046885007577778415\ \(0\)\
\-\ bed\\:\\ 0\\.04672237977117793\ \(0\)\
\-\ effective\\:\\ 0\\.04595603284867122\ \(0\)\
\-\ account\\:\\ 0\\.04581131008763313\ \(0\)\
\-\ resulted\\:\\ 0\\.04581131008763313\ \(0\)\
\-\ 61\\:\\ 0\\.045669195086309004\ \(0\)\
\-\ state\\:\\ 0\\.045392423910103355\ \(0\)\
\-\ may\\:\\ 0\\.04528206433616478\ \(0\)\
\-\ nearly\\:\\ 0\\.04486641775638666\ \(0\)\
\-\ 2007\\:\\ 0\\.04449372625918639\ \(0\)\
\-\ information\\:\\ 0\\.04449372625918639\ \(0\)\
\-\ mortality\\:\\ 0\\.04425470284056731\ \(0\)\
\-\ legs\\:\\ 0\\.04425470284056731\ \(0\)\
\-\ branch\\:\\ 0\\.0441378537525195\ \(0\)\
\-\ topic\\:\\ 0\\.04305572529504765\ \(0\)\
\-\ treatment\\:\\ 0\\.04286347061242716\ \(0\)\
\-\ septic\\:\\ 0\\.04275806094322567\ \(0\)\
\-\ types\\:\\ 0\\.04183991280357823\ \(0\)\
\-\ anticoagulation\\:\\ 0\\.0417537133752781\ \(0\)\
\-\ within\\:\\ 0\\.0414431949645657\ \(0\)\
\-\ progression\\:\\ 0\\.04125541068939404\ \(0\)\
\-\ has\\:\\ 0\\.0411014140839639\ \(0\)\
\-\ length\\:\\ 0\\.04101758857596089\ \(0\)\
\-\ pancreatic\\:\\ 0\\.04078672811870931\ \(0\)\
\-\ women\\:\\ 0\\.04048906376688733\ \(0\)\
\-\ represents\\:\\ 0\\.04020222600452512\ \(0\)\
\-\ leading\\:\\ 0\\.0399937424339713\ \(0\)\
\-\ veins\\:\\ 0\\.03992545482831947\ \(0\)\
\-\ states\\:\\ 0\\.03952769815372193\ \(0\)\
\-\ main\\:\\ 0\\.03921090178722346\ \(0\)\
\-\ embolization\\:\\ 0\\.03921090178722346\ \(0\)\
\-\ evident\\:\\ 0\\.038670884670735615\ \(0\)\
\-\ those\\:\\ 0\\.03849879415252257\ \(0\)\
\-\ apparent\\:\\ 0\\.03763947773329598\ \(0\)\
\-\ shaped\\:\\ 0\\.03758875621326377\ \(0\)\
\-\ resulting\\:\\ 0\\.03743851987689945\ \(0\)\
\-\ difficult\\:\\ 0\\.037339928978363135\ \(0\)\
\-\ point\\:\\ 0\\.03719431556527929\ \(0\)\
\-\ segment\\:\\ 0\\.03714636910040372\ \(0\)\
\-\ below\\:\\ 0\\.03705134181615279\ \(0\)\
\-\ best\\:\\ 0\\.036201476769157234\ \(0\)\
\-\ diameter\\:\\ 0\\.03615918621645159\ \(0\)\
\-\ stage\\:\\ 0\\.035828785271956966\ \(0\)\
\-\ arteries\\:\\ 0\\.03570836813626497\ \(0\)\
\-\ especially\\:\\ 0\\.035589761853337884\ \(0\)\
\-\ ii\\:\\ 0\\.03547291276529008\ \(0\)\
\-\ upon\\:\\ 0\\.0353959641629172\ \(0\)\
\-\ where\\:\\ 0\\.03535776956438702\ \(0\)\
\-\ term\\:\\ 0\\.03528193081485253\ \(0\)\
\-\ vessels\\:\\ 0\\.034913304419850334\ \(0\)\
\-\ additional\\:\\ 0\\.03487737192406537\ \(0\)\
\-\ filling\\:\\ 0\\.03484160238800485\ \(0\)\
\-\ extensive\\:\\ 0\\.03466514829060278\ \(0\)\
\-\ complex\\:\\ 0\\.03466514829060278\ \(0\)\
\-\ unknown\\:\\ 0\\.03409311995599625\ \(0\)\
\-\ specific\\:\\ 0\\.03409311995599625\ \(0\)\
\-\ causes\\:\\ 0\\.03399634365983374\ \(0\)\
\-\ result\\:\\ 0\\.03368207223787232\ \(0\)\
\-\ used\\:\\ 0\\.03368207223787232\ \(0\)\
\-\ management\\:\\ 0\\.033232965968692504\ \(0\)\
\-\ lungs\\:\\ 0\\.033203915588951735\ \(0\)\
\-\ defect\\:\\ 0\\.03300350486371169\ \(0\)\
\-\ compression\\:\\ 0\\.03294716770144653\ \(0\)\
\-\ based\\:\\ 0\\.032590469702164615\ \(0\)\
\-\ vein\\:\\ 0\\.03224920782173862\ \(0\)\
\-\ pelvis\\:\\ 0\\.03146717638515724\ \(0\)\
\-\ new\\:\\ 0\\.03112568715309802\ \(0\)\
\-\ underwent\\:\\ 0\\.030993126567458316\ \(0\)\
\-\ left\\:\\ 0\\.030695015638745465\ \(0\)\
\-\ available\\:\\ 0\\.030525286688070172\ \(0\)\
\-\ extending\\:\\ 0\\.030504666626173776\ \(0\)\
\-\ size\\:\\ 0\\.030463587527150414\ \(0\)\
\-\ first\\:\\ 0\\.030361816190173092\ \(0\)\
\-\ flow\\:\\ 0\\.029967375542188604\ \(0\)\
\-\ long\\:\\ 0\\.029833853165293148\ \(0\)\
\-\ should\\:\\ 0\\.0293568091874872\ \(0\)\
\-\ known\\:\\ 0\\.029128688281907133\ \(0\)\
\-\ such\\:\\ 0\\.028940686182591102\ \(0\)\
\-\ usually\\:\\ 0\\.02832367947108633\ \(0\)\
\-\ abdomen\\:\\ 0\\.027452180227203103\ \(0\)\
\-\ evaluation\\:\\ 0\\.0274382082675121\ \(0\)\
\-\ month\\:\\ 0\\.027368717340600337\ \(0\)\
\-\ syndrome\\:\\ 0\\.027123500620380738\ \(0\)\
\-\ 10\\:\\ 0\\.026308617118959574\ \(0\)\
\-\ blood\\:\\ 0\\.026129219638589732\ \(0\)\
\-\ therapy\\:\\ 0\\.02585040996008978\ \(0\)\
\-\ evidence\\:\\ 0\\.0255371195015919\ \(0\)\
\-\ these\\:\\ 0\\.025406570272557296\ \(0\)\
\-\ patients\\:\\ 0\\.025310057140812595\ \(0\)\
\-\ man\\:\\ 0\\.023818943725575935\ \(0\)\
\-\ chest\\:\\ 0\\.023748678947427496\ \(0\)\
\-\ without\\:\\ 0\\.023731210127035017\ \(0\)\
\-\ tumor\\:\\ 0\\.02353305127024224\ \(0\)\
\-\ diagnosis\\:\\ 0\\.0233231621102529\ \(0\)\
\-\ it\\:\\ 0\\.023030408822838026\ \(0\)\
\-\ have\\:\\ 0\\.022475613595686558\ \(0\)\
\-\ up\\:\\ 0\\.02225549226211515\ \(0\)\
\-\ multiple\\:\\ 0\\.02200621560306084\ \(0\)\
\-\ contrast\\:\\ 0\\.02186034570084075\ \(0\)\
\-\ that\\:\\ 0\\.019524529487269803\ \(0\)\
\-\ be\\:\\ 0\\.018251164773922707\ \(0\)\
\-\ as\\:\\ 0\\.01807459505402627\ \(0\)\
\-\ not\\:\\ 0\\.017761488214703972\ \(0\)\
\-\ with\\:\\ 0\\.017619711288526727\ \(0\)\
\-\ ct\\:\\ 0\\.017128603772076742\ \(0\)\
\-\ this\\:\\ 0\\.015459814992941653\ \(0\)\
\-\ right\\:\\ 0\\.014916471796522017\ \(0\)\
\-\ year\\:\\ 0\\.013865427552893689\ \(0\)\
